Fsd Pharma (TSE:HUGE) has released an update.
FSD Pharma Inc. has announced positive findings from their Phase-1 clinical trial of Lucid-21-302 (Lucid-MS), a pioneering treatment for Multiple Sclerosis (MS), at the ACTRIMS 2024 Forum. The trial revealed that the drug is safe and well-tolerated across a range of doses and exhibits good oral absorption, showing promise in preventing demyelination in MS patients. The results, which may have significant implications for MS treatment, are now accessible on the company’s website.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
